Centessa Pharmaceuticals Analyst Ratings
Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target
Centessa Pharmaceuticals Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results
Analysts' Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
Upgraded Buy Rating and Price Target for Centessa Pharmaceuticals on SerpinPC's Market Potential
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Centessa Pharmaceuticals (CNTA) and G1 Therapeutics (GTHX)
Centessa Pharmaceuticals: Buy Rating Backed by Strong Pipeline and Positive Drug Data
Buy Rating Affirmed for Centessa Pharmaceuticals on Strong R&D Prospects and Market Potential
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA) and Vertex Pharmaceuticals (VRTX)
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lantheus (LNTH) and Carisma Therapeutics (CARM)
Jefferies Upgrades Centessa to Buy, Cites Upcoming Data for Narcolepsy Drug
Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals' Growth Potential: Diversified Drug Pipeline and Market Opportunities – A Buy Rating Analysis
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $8
Centessa Pharmaceuticals Analyst Ratings
Hold Rating for Centessa Pharmaceuticals: Potential of ORX750 and Considerations for Future Development